January 12, 2022 04:44 PM ESTUpdated January 14, 09:00 AM
Manufacturing

#JPM22: Catal­ent CEO John Chimin­s­ki with John Car­roll — Our pre­dic­tions for the bio­phar­ma in­dus­try in 2022

John Carroll

Editor & Founder

Dur­ing our JPM22 week of events, I had a chance to sit down with Catal­ent CEO John Chimin­s­ki for our an­nu­al fore­cast for the year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times